| 
 
 
|  |  
|  Dezocine
 |  
| Systematic (IUPAC) name |  
| (5α,11α,13S)-13-amino-5,6,7,8,9,10,11,12-octahydro -5-methyl-5,11-methanobenzocyclodecen-3-ol |  
| Identifiers |  
| CAS number | 53648-55-8 |  
| ATC code | N02AX03 |  
| PubChem | 40841 |  
| DrugBank | APRD00912 |  
| Chemical data |  
| Formula | C16H23NO |  
| Mol. mass | 245.36 g/mol |  
| Synonyms | Dezocine, Dalgan |  
| Pharmacokinetic data |  
| Bioavailability | ? |  
| Metabolism | Hepatic |  
| Half life | 2.2 hours |  
| Excretion | ? |  
| Therapeutic considerations |  
| Pregnancy cat. | ?
 |  
| Legal status |  |  
| Routes | intramuscular injection |  Dezocine (Dalgan, WY-16225) is an opioid analgesic related to pentazocine, with a similar profile of effects that include analgesic action and euphoria at low doses,[1] but produces dysphoria and hallucinations at high doses, most likely due to action at κ-opioid receptors.[2][3] 
 Dezocine has been found to be an effective painkiller comparable to meperidine (pethidine),[4] and so is a more effective analgesic than pentazocine, but causes relatively more respiratory depression than pentazocine.[5] It is a useful drug for the treatment of pain,[6] but side effects such as dizziness limit its clinical application,[7] and it can produce opioid withdrawal syndrome in patients already dependent on other opioids.[8]
 Dezocine is unusual among opioids as it is the only primary amine known to be an active opioid. It is a mixed agonist-antagonist as with other drugs in this class,[9] and despite having a stronger respiratory depressant effect than morphine, dezocine shows a ceiling effect on its respiratory depressive action so above a certain dose this effect does not get any more severe.[10] 
 
 
   References 
^ Zacny JP, Lichtor JL, de Wit H. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. Anesthesia and Analgesia. 1992 Apr;74(4):523-30.^ Jacobs AM, Youngblood F. Opioid receptor affinity for agonist-antagonist analgesics. Journal of the American Podiatric Medical Association. 1992 Oct;82(10):520-4.^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacology. 2006 Jan 25;6:3.^ Camu F, Gepts E. Analgesic properties of dezocine for relief of postoperative pain. Acta Anaesthesiologica Belgica. 1979;30 Suppl:183-91.^ Wuest HP, Bellville JW. The respiratory effects of dezocine and pentazocine in man. Journal of Clinical Pharmacology. 1979 Apr;19(4):205-10.^ O'Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Aug;38(2):226-48.^ Oosterlinck W, Verbaeys A. Preliminary clinical experience with dezocine, a new potent analgesic. Current Medical Research and Opinion. 1980;6(7):472-4.^ Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist effects of dezocine in opioid-dependent humans.
Clinical Pharmacology and Therapeutics. 1996 Aug;60(2):206-17.^ Young AM, Stephens KR, Hein DW, Woods JH. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. Journal Pharmacology and Experimental Therapeutics. 1984 Apr;229(1):118-26.^ Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clinical Pharmacology and Therapeutics. 1984 Mar;35(3):367-73.
 | Opioids | 
|---|
 | Opiate derivatives |  | 
|---|
 | Morphinans |  | 
|---|
 | Benzomorphans |  | 
|---|
 | 4-Phenylpiperidines |  | 
|---|
 | Open Chain Opioids | 
| Amidones |  |  
| Methadols |  |  
| Moramides |  |  
| Thiambutenes |  |  
| Phenalkoxams |  |  
| Ampromides |  |  
| Others | Lefetamine |  | 
|---|
 | Anilidopiperidines |  | 
|---|
 | Oripavine derivatives |  | 
|---|
 | Phenazepines |  | 
|---|
 | Pirinitramides |  | 
|---|
 | Benzimidazoles |  | 
|---|
 | Others |  | 
|---|
 |